MyoGene Bio develops therapies for muscle diseases, starting with a gene-editing therapy for Duchenne muscular dystrophy.
MyoGene Bio has raised $400K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in November 2025.
MyoGene Bio's investors include MassChallenge, Parent Project Muscular Dystrophy, Duchenne UK, CureDuchenne Ventures.
MyoGene Bio is headquartered in Los Angeles, United States.
MyoGene Bio develops therapies for muscle diseases, starting with a gene-editing therapy for Duchenne muscular dystrophy.
MyoGene Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MyoGene Bio — Funding & Investors." VCBacked, November 4, 2025, https://www.vcbacked.co/company/myogene-bio. Accessed July 20, 2026.
VCBacked. (2025). MyoGene Bio — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/myogene-bio
{{cite web |title=MyoGene Bio — Funding & Investors |url=https://www.vcbacked.co/company/myogene-bio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated